Publication date: Jul 18, 2025
Tuberculosis (TB) remains one of the leading global public health concerns and is among the top ten causes of death from a single infectious agent. China ranks third worldwide in total TB burden, with a substantial proportion of cases classified as drug-susceptible TB (DS-TB). Despite the availability of effective standard treatment regimens, the current 6-month therapy duration poses challenges in terms of patient adherence, resource allocation, and overall treatment success. In recent years, ultrashort-course regimens for DS-TB have been proposed and evaluated in clinical studies, showing promising results in improving adherence, reducing treatment duration, and maintaining or even enhancing treatment efficacy. However, these regimens have primarily been studied in younger populations, with limited data available for elderly patients. Older adults often present with age-related physiological changes, multiple comorbidities, and an increased risk of adverse drug reactions, which may affect both the efficacy and safety of treatment. Therefore, this study aims to assess the therapeutic effectiveness and safety profile of a novel ultrashort-course regimen for drug-susceptible pulmonary TB specifically in patients aged 65 years and older.
| Concepts | Keywords |
|---|---|
| China | Blood |
| Diabetes | Drug |
| Month | Efficacy |
| Therapy | Elderly |
| Ultrashort | Older |
| Patients | |
| Pulmonary | |
| Regimen | |
| Regimens | |
| Susceptible | |
| Tb | |
| Treatment | |
| Tuberculosis | |
| Ultrashort | |
| Years |